Pasithea Therapeutics annual current ratio
2021
2022
2023
2024
2025
Pasithea Therapeutics Current Ratio Growth & History (KTTA)
Pasithea Therapeutics's current ratio was 11.35 for fiscal 2025.
View full Pasithea Therapeutics company overviewPasithea Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 11.35 | 4.77 | +72.52% |
| 2024 | 2024-12-31 | 6.58 | 0.24 | +3.83% |
| 2023 | 2023-12-31 | 6.34 | −11.81 | −65.08% |
| 2022 | 2022-12-31 | 18.15 | −101.02 | −84.77% |
| 2021 | 2021-12-31 | 119.17 | — | — |
Pasithea Therapeutics quarterly current ratio
As of Dec 31, 2020
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 26.25 | 21.28 | +427.91% |
| Q1 2026 | 2026-03-31 | 35.40 | 31.56 | +821.86% |
| Q4 2025 | 2025-12-31 | 11.35 | 4.77 | +72.52% |
| Q3 2025 | 2025-09-30 | 4.02 | −10.79 | −72.88% |
| Q2 2025 | 2025-06-30 | 4.97 | −1.22 | −19.75% |
| Q1 2025 | 2025-03-31 | 3.84 | −1.51 | −28.19% |
| Q4 2024 | 2024-12-31 | 6.58 | 0.24 | +3.83% |
| Q3 2024 | 2024-09-30 | 14.81 | 4.64 | +45.71% |
| Q2 2024 | 2024-06-30 | 6.20 | −6.38 | −50.74% |
| Q1 2024 | 2024-03-31 | 5.35 | −9.31 | −63.52% |
| Q4 2023 | 2023-12-31 | 6.34 | −11.81 | −65.08% |
| Q3 2023 | 2023-09-30 | 10.16 | −19.21 | −65.40% |
| Q2 2023 | 2023-06-30 | 12.58 | −38.59 | −75.42% |
| Q1 2023 | 2023-03-31 | 14.66 | −102.82 | −87.52% |
| Q4 2022 | 2022-12-31 | 18.15 | −101.02 | −84.77% |
| Q3 2022 | 2022-09-30 | 29.37 | −10.46 | −26.25% |
| Q2 2022 | 2022-06-30 | 51.17 | — | — |
| Q1 2022 | 2022-03-31 | 117.48 | — | — |
| Q4 2021 | 2021-12-31 | 119.17 | 81.61 | +217.33% |
| Q3 2021 | 2021-09-30 | 39.83 | — | — |
| As of Dec 31, 2020 | 2020-12-31 | 37.55 | — | — |
Pasithea Therapeutics current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Pasithea Therapeutics's current ratio decreased from 119.17 to 11.35, a change of −107.81. The latest reported quarter, Q2 2026, shows 26.25.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pasithea Therapeutics source filings ↗